about
An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machineDiscovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjectsTargeting Cell Survival Proteins for Cancer Cell DeathMechanisms of resistance in castration-resistant prostate cancer (CRPC)Maximizing the Therapeutic Potential of HSP90 InhibitorsNew molecular targets in mantle cell lymphomaMolecular chaperones and co-chaperones in Parkinson diseaseEGFR/HER-targeted therapeutics in ovarian cancerThe molecular chaperone Hsp90α is required for meiotic progression of spermatocytes beyond pachytene in the mouseThreonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activityHsp90 governs dispersion and drug resistance of fungal biofilmsPrediction of promiscuous p-glycoprotein inhibition using a novel machine learning schemeGlobal analysis of the evolution and mechanism of echinocandin resistance in Candida glabrataThe co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922Targeting heat shock protein 90 for the treatment of malignant pheochromocytomaHsp70 Isoforms Are Essential for the Formation of Kaposi's Sarcoma-Associated Herpesvirus Replication and Transcription CompartmentsHeat shock protein 90 inhibition: rationale and clinical potential.Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays.Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosusProteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent mannerMolecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesGambogic acid, a natural product inhibitor of Hsp90High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.Novobiocin analogues with second-generation noviose surrogates.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluationPreclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulationHeat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesisSelective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.17-AAG kills intracellular Leishmania amazonensis while reducing inflammatory responses in infected macrophages.3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraTargeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivoDevelopment of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.Heat shock proteins in breast cancer progression--a suitable case for treatment?Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy.Molecular targeted approaches in mantle cell lymphoma.
P2860
Q21134999-1F220A2C-233C-4D29-8FFF-B815AFDD0776Q24600166-1885AE22-C344-4C95-9FAD-C408C663EC3EQ26765447-DF2A1144-597A-495F-8F6C-10062E77909FQ26774221-E2A8D71A-C348-419D-8287-CF5D5F7F97A2Q26798318-18F72F79-50C1-4B5A-A2FF-AC0FA344FD70Q26821766-30487D6F-ABC6-4F26-9C70-150089A6C782Q26828834-2FB98377-18E6-4282-88DD-879B9517EA2DQ26863231-C8538607-301D-496C-B200-2FF16E3A326EQ27438098-C59CB64E-0688-46D6-BCB3-1981D8743B02Q28307703-A858C536-FCB5-4446-9ACF-2196E0C72575Q28476836-634C519B-7431-452B-8AAD-9E509F55B0E0Q28481547-59AAD1E6-46A9-4ABD-8376-7888A5B6C7C3Q28483785-30B0FA5A-A06C-4252-911D-39274D9D9267Q28485166-9002C5AC-0057-460C-8443-B5987062575FQ28486170-7974FA75-FD26-4AAC-8D46-50672D4D1700Q28551082-4A1647C3-980F-489B-90A9-ED3E9E6F25ADQ30418761-0C39521D-FBE2-4296-87C9-934F3315C0C6Q30559962-DD6DCACD-2CD4-402C-901C-03B1FE0A284BQ33577386-04D9371C-1DC7-4AA9-A84A-69958BE65182Q33668999-2B580AEA-A67A-4774-8424-221E276CF3F5Q33676779-F4E61779-B22E-4B00-B056-B371B28A5DB4Q33715640-169EC893-0385-4972-98C2-27B2947FB3F7Q33870322-B6901D2C-C5D7-490F-891A-A0D7EB117C57Q33877440-EA056E85-178A-46F7-938D-373C8BAF2C55Q34010496-1C9313B8-5CD5-41AA-ACD0-2C5E4C6979A6Q34102029-F79328C0-CC25-4040-84B6-2352405DC004Q34120364-4B327B5C-6C24-4A06-B151-6549126DAC4CQ34267286-6FA7499E-7DF9-453D-84FF-8D72E664C940Q34268075-9CD71E13-4CF0-4EF4-8806-8280756CD5CCQ34401008-73FC45FF-D9D2-48C1-BAD5-B1AD1F59D9DCQ34435827-293B000C-13B7-4790-94EA-2B5A788AD6EAQ34478035-2B776947-5631-40F1-958E-8662B89A7756Q34547161-06E6FF8D-1747-4F07-9EE1-1AEC35BD60E8Q34568868-A85E6558-3575-4915-B78D-578307EB37C3Q34628001-C8669D00-C184-49AC-AEC6-F3D964A0104EQ34690918-EC02AA14-15F3-4888-80B4-010AEBE191D2Q35017614-AA71065E-E030-473E-84C3-DE8D1BB04BD8Q35070272-178EFB27-6484-4362-B2D1-0090AD6BC89DQ35116243-D0AB570B-0F0B-486A-8EA2-09D53FA47A6CQ35127368-7204EDA2-C742-4BE6-B065-1612A25F7A48
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Update on Hsp90 inhibitors in clinical trial.
@ast
Update on Hsp90 inhibitors in clinical trial.
@en
type
label
Update on Hsp90 inhibitors in clinical trial.
@ast
Update on Hsp90 inhibitors in clinical trial.
@en
prefLabel
Update on Hsp90 inhibitors in clinical trial.
@ast
Update on Hsp90 inhibitors in clinical trial.
@en
P2093
P1476
Update on Hsp90 inhibitors in clinical trial
@en
P2093
P304
P356
10.2174/156802609789895728
P577
2009-01-01T00:00:00Z